surmount tirzepatide trials Presented today at #ECO2026 ⤵️ The SURMOUNT-MAINTAIN trial found that continuing at the maximum tolerated dose maintained bodyweight reduction and health-related benefits in adults with obesity. Explore the research: https://t.co/RjLxWa5qjV Semaglutide vs. Tirzepatide for Obesity

Based on this information, for most patients, a tesofensine dose of 0.5 mg or lower appears to be the most suitable option

Remember, keeping track of your progress is important, especially if youre using weight loss medications like Semaglutide and Tirzepatide

Final Thoughts In conclusion, tirzepatide is a promising new medication for the treatment of type 2 diabetes, but it does carry the risk of hypoglycemia

Studies have demonstrated that #Tirzepatide led to a 63% mean reduction in restricted/obstructed breathing events per hour in patients with moderate to severe obstructive sleep apnea and a reduction in average weight 5